When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?

When a death is reported in a clinical trial, what should the investigator provide to the sponsor and the IRB/IEC?

• A. Any additional information requested by sponsor and IRB/IEC
• B. The basic death notification only
• C. A copy of the patient's medical records without sponsor knowledge
• D. The final study report

Answer: (A)

When a death occurs in a clinical trial, safety oversight requires the investigator to promptly inform the sponsor and the IRB/IEC and to provide whatever information they request to assess safety and the conduct of the trial. The sponsor and IRB/IEC rely on this information to determine if the death is related to the investigational product, to evaluate risks to participants, and to decide whether any changes to the protocol or monitoring are needed. The initial notification should be followed by any additional data requested, such as clinical details around the death, the subject’s medical history, concomitant medications, timing of doses, and relevant medical records or autopsy findings, all shared with proper permissions and privacy protections. The final study report appears after the trial ends and does not substitute for the real-time safety information needed during the study. Providing medical records without sponsor oversight would bypass required safety review.

When a death occurs in a clinical trial, safety oversight requires the investigator to promptly inform the sponsor and the IRB/IEC and to provide whatever information they request to assess safety and the conduct of the trial. The sponsor and IRB/IEC rely on this information to determine if the death is related to the investigational product, to evaluate risks to participants, and to decide whether any changes to the protocol or monitoring are needed. The initial notification should be followed by any additional data requested, such as clinical details around the death, the subject’s medical history, concomitant medications, timing of doses, and relevant medical records or autopsy findings, all shared with proper permissions and privacy protections. The final study report appears after the trial ends and does not substitute for the real-time safety information needed during the study. Providing medical records without sponsor oversight would bypass required safety review.